Conditions: Alzheimer's Disease
Keywords: Alzheimer's disease RVT-101 donepezil
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 1099
Healthy volunteers: no

Brief summary:
This 12-month open-label study will provide further information regarding the long-term safety and tolerability of intepirdine (RVT-101) for subjects with Alzheimer's disease who have completed the double-blind, placebo-controlled, lead-in study RVT-101-3001 (double-blind study).

Detailed description:
This 12-month open-label study will provide further information regarding the long-term safety and tolerability of intepirdine (RVT-101) for subjects with Alzheimer's disease who have completed the double-blind, placebo-controlled, lead-in study RVT-101-3001. Various background therapies, including acetylcholinesterase inhibitors and memantine, will be allowed.

Arms:
arm 1: once daily, oral tablets

Interventions: intervention 1: RVT-101 35 mg tablets
Intervention descriptions: intervention 1: once daily, oral tablets

Protocol document:
Prot_SAP_000.pdf: 
TITLE PAGE
CLINICAL STUDY PROTOCOL
Title:
A Long-Term, Open-Label Extension Study of the Safety and 
Tolerability of RVT-101 in Subjects with Alzheimer’s Disease
Sponsor
Axovant Sciences Ltd.
Compound Name:
RVT-101
Protocol Number
RVT-101-3002
Indication
Alzheimer’s disease 
Development Phase
Phase 3
IND #
78,094
Version/
Date:
2.0
12 May 2016
Axovant Sciences
Study Director
Ilise Lombardo, MD
Telephone: +1 646 495 8197
Email: ilise.lombardo@axovant.com
Medical Monitor
Meera Jessani, MD
Telephone:  +1 610 964 2012
Mobile:  +1 310 728 5684
Email:  Meera.jessani@wwctrials.com
Confidentiality Statement
The information contained in this document, particularly unpublished data, is the property or under control 
of Axovant Sciences Ltd., and is provided to you in confidence as an investigator, potential investigator,
or consultant, for review by you, your staff, and an applicable Institutional Review Board or Independent 
Ethics Committee. The information is only to be used by you in connection with authorized clinical studies 
of the investigational product described in the protocol. You will not disclose any of the information to 
others without written authorization from Axovant Sciences Ltd., except to the extent necessary to obtain 
informed consent from those persons to whom the investigational product may be administered.




Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 3 of 54
12 May 2016
CONFIDENTIAL
MEDICAL MONITOR/SPONSOR INFORMATION PAGE
Medical Monitor/Serious Adverse Event Contact Information:
Role and 
Region
Name
Daytime Phone Number and 
Email Address
After-Hours 
Phone/Cell/
Pager Number
Fax Number
WCT Site 
Address
Primary Medical Monitor
Americas
Meera 
Jessani, 
MD
+1 610 964 2012 
Meerra.jessani@wwctrials.com
+1 310 728 5684
+1 610 225 0050
1000 
Continental 
Drive, King of 
Prussia, PA 
19406, USA
Secondary Medical Monitors
Western and 
Central 
Europe
Manolo 
Beelke, 
MD, PhD
+49 (0) 89 8905 8422 
manolo.beelke@wwctrials.com
+49 (0) 17 3618 9707
+49 (0) 89 8905 8423
Landsberger 
Str.
63A, 82110 
Germering, 
Germany
Eastern 
Europe and 
Asia Pacific
Olga 
Kolotilina, 
MD
+7 384 245 46 70 
olga.kolotilina@wwctrials.com
+7 906 925 18 12
+7 384 245 46 73
536, 12, N. 
Ostrovskogo 
Str., 
Kemerovo, 
650000, 
Russia
Serious 
Adverse 
Event (SAE)
Contact
Information
For SAE reporting information, see Section 8.2.1.1.7, Reporting of Serious Adverse Events.
For questions or discussions regarding SAEs, contact Medical Monitor as shown above.
Study Sponsor
This study is sponsored by Axovant Sciences Ltd. 
Axovant Sciences Ltd. Registered Address:
Clarendon House
2 Church Street
Hamilton HM11
Bermuda
US Agent and Regulatory Contact:
Axovant Sciences Inc.
320 West 37th Street, 5th Floor
New York, NY  10018
USA


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 4 of 54
12 May 2016
CONFIDENTIAL
INVESTIGATOR STATEMENT
I agree to conduct the study in compliance with the protocol.
I acknowledge that I am responsible for overall study conduct. I agree to personally conduct or 
supervise the described study.
I agree to ensure that all associates, colleagues, and employees assisting in the conduct of the 
study are informed about and fulfil their obligations. Mechanisms are in place to ensure that 
site staff receives the appropriate information throughout the study.
Principal Investigator Name (Printed)
Signature
Date
Site


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 5 of 54
12 May 2016
CONFIDENTIAL
TABLE OF CONTENTS
PAGE
TITLE PAGE................................................................................................................................................ 1 
SPONSOR SIGNATURE PAGE ................................................................................................................. 2 
MEDICAL MONITOR/SPONSOR INFORMATION PAGE ..................................................................... 3 
INVESTIGATOR STATEMENT ................................................................................................................ 4 
TABLE OF CONTENTS.............................................................................................................................. 5 
LIST OF TABLES........................................................................................................................................ 8 
LIST OF FIGURES ...................................................................................................................................... 9 
1. 
ABBREVIATIONS ............................................................................................................................ 10 
2. 
PROTOCOL SUMMARY.................................................................................................................. 12 
3. 
INTRODUCTION .............................................................................................................................. 14 
3.1. 
Background............................................................................................................................ 14 
3.1.1. 
Alzheimer’s Disease.............................................................................................. 14 
3.1.2. 
RVT-101 ............................................................................................................... 15 
3.2. 
Study Rationale...................................................................................................................... 16 
3.3. 
Dose Rationale....................................................................................................................... 16 
4. 
OBJECTIVES AND ENDPOINTS .................................................................................................... 17 
5. 
STUDY DESIGN................................................................................................................................ 18 
5.1. 
Overall Design ....................................................................................................................... 18 
5.2. 
Study Schematic .................................................................................................................... 18 
6. 
SUBJECT POPULATION.................................................................................................................. 20 
6.1. 
Type and Number of Subjects................................................................................................ 20 
6.2. 
Inclusion Criteria ................................................................................................................... 20 
6.3. 
Exclusion Criteria .................................................................................................................. 21 
6.4. 
Other Eligibility Criteria Considerations............................................................................... 23 
6.5. 
Screening Failures.................................................................................................................. 23 
6.6. 
Withdrawal Criteria ............................................................................................................... 23 
6.6.1. 
Reasons for Withdrawal........................................................................................ 23 
6.6.2. 
Subject Withdrawal Procedures ............................................................................ 24 
7. 
STUDY TREATMENT...................................................................................................................... 25 
7.1. 
Investigational Product and Other Study Treatment.............................................................. 25 
7.2. 
Randomization/Treatment Assignment.................................................................................. 25 
7.3. 
Blinding ................................................................................................................................. 25 
7.4. 
Packaging and Labeling......................................................................................................... 25 
7.5. 
Preparation/Handling/Storage/Accountability....................................................................... 26 
7.6. 
Compliance with Investigational Product Administration..................................................... 27 


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 6 of 54
12 May 2016
CONFIDENTIAL
7.7.
Treatment of Investigational Product Overdose .................................................................... 27
7.8. 
Treatment after the End of the Study..................................................................................... 28 
7.9. 
Concomitant Medications and Non-Drug Therapies ............................................................. 28 
7.9.1. 
Permitted Medications and Non-Drug Therapies.................................................. 28 
7.9.2. 
Prohibited Medications and Non-Drug Therapies................................................. 28 
7.10. 
Lifestyle and/or Dietary Restrictions..................................................................................... 30 
7.10.1. 
Meals and Dietary Restrictions ............................................................................. 30 
8. 
STUDY ASSESSMENTS AND PROCEDURES.............................................................................. 31 
8.1. 
Time and Events .................................................................................................................... 31 
8.2. 
Study Assessments and Procedures ....................................................................................... 35 
8.2.1.
Safety and Screening Assessments ....................................................................... 35
8.2.1.1. 
Adverse Events.................................................................................. 35 
8.2.1.2. 
Safety Monitoring Committee........................................................... 40 
8.2.1.3. 
Physical and Neurological Examinations.......................................... 40 
8.2.1.4. 
Vital Signs......................................................................................... 40 
8.2.1.5. 
Electrocardiogram ............................................................................. 40 
8.2.1.6. 
Clinical Safety Laboratory Assessments........................................... 41 
8.2.1.7. 
Assessment of Suicidality ................................................................. 42 
8.2.1.8. 
Pregnancy.......................................................................................... 42 
8.2.2. 
Efficacy Assessments............................................................................................ 43
8.2.2.1. 
Dependence Scale.............................................................................. 43 
8.2.2.2. 
EuroQOL-5D..................................................................................... 43 
9. 
DATA MANAGEMENT.................................................................................................................... 44
10. STATISTICAL CONSIDERATIONS AND DATA ANALYSES .................................................... 45 
10.1. 
Hypotheses............................................................................................................................. 45 
10.2. 
Sample Size Considerations................................................................................................... 45 
10.3. 
Data Analysis Considerations................................................................................................ 45 
10.3.1. 
Analysis Populations............................................................................................. 45 
10.3.2. 
Interim Analysis.................................................................................................... 45 
10.4. 
Key Elements of Analysis Plan.............................................................................................. 45 
10.4.1. 
Primary Efficacy Analyses.................................................................................... 45 
10.4.2. 
Safety Analyses..................................................................................................... 45 
10.4.2.1. 
Adverse Events.................................................................................. 46 
10.4.2.2. 
Clinical Laboratory Tests .................................................................. 46 
10.4.2.3. 
Vital Signs, Electrocardiograms, Physical Findings, and Other 
Safety Evaluations............................................................................. 46 
10.4.2.4. 
Suicidality.......................................................................................... 46 
10.4.3. 
Other Analyses...................................................................................................... 47 
11. RESPONSIBILITIES ......................................................................................................................... 48 
11.1. 
Investigator Responsibilities.................................................................................................. 48 
11.1.1.
Good Clinical Practice .......................................................................................... 48 


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 7 of 54
12 May 2016
CONFIDENTIAL
11.1.2.
Institutional Review Board/Independent Ethics Committee Approval................. 48
11.1.3. 
Informed Consent.................................................................................................. 49 
11.1.4. 
Confidentiality....................................................................................................... 49 
11.1.5. 
Study Files and Retention of Records................................................................... 49 
11.1.6. 
Electronic Case Report Forms............................................................................... 50 
11.1.7. 
Drug Accountability.............................................................................................. 50 
11.1.8. 
Inspections............................................................................................................. 51 
11.1.9. 
Protocol Compliance............................................................................................. 51 
11.2. 
Sponsor Responsibilities........................................................................................................ 51 
11.2.1. 
Protocol Modifications.......................................................................................... 51 
11.2.2. 
Study Report and Publications.............................................................................. 51 
11.2.3. 
Posting of Information on Publicly Available Clinical Trial Registers ................ 52 
11.3. 
Joint Investigator/Sponsor Responsibilities........................................................................... 52 
11.3.1. 
Access to Information for Monitoring................................................................... 52 
11.3.2. 
Access to Information for Auditing or Inspections............................................... 52 
11.3.3. 
Study Discontinuation........................................................................................... 52 
12. REFERENCES ................................................................................................................................... 53 


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 8 of 54
12 May 2016
CONFIDENTIAL
LIST OF TABLES
PAGE
Table 1. 
List of Prohibited Medications ......................................................................................... 30 
Table 2. 
Time and Events Schedule................................................................................................ 33 
Table 3. 
Protocol-Required Screening and Safety Laboratory Assessments.................................. 41 


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 9 of 54
12 May 2016
CONFIDENTIAL
LIST OF FIGURES
PAGE
Figure 1. 
Study Design..................................................................................................................... 19 


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 10 of 54
12 May 2016
CONFIDENTIAL
1.
ABBREVIATIONS
Abbreviation
Definition
5HT6
5-hydroxytryptamine sub-type 6
AD
Alzheimer’s disease
ADAS-Cog
Alzheimer’s Disease Assessment Scale – Cognitive Subscale
ADCS-ADL
Alzheimer’s Disease Cooperative Study - Activities of Daily Living
AE
adverse event
ALT
alanine aminotransferase
AST
aspartate aminotransferase
BUN
blood urea nitrogen
CDR-SB
Clinical Dementia Rating – Sum of Boxes
CFR
Code of Federal Regulations
CIBIC+
Clinician’s Interview-Based Impression of Change – plus carer 
interview
C-SSRS
Columbia Suicide Severity Rating Scale
DS
Dependence Scale
ECG
electrocardiogram
eCRF
electronic case report form
EDC
electronic data capture
EQ-5D
EuroQOL 5 dimensions questionnaire
FDA
Food and Drug Administration
GGT
gamma glutamyltransferase
hCG
human chorionic gonadotropin
ICF
informed consent form
ICH
International Conference on Harmonisation
IEC
Independent Ethics Committee
IRB
Institutional Review Board
MCH
mean corpuscular hemoglobin
MCV
mean corpuscular volume
MedDRA
Medical Dictionary for Regulatory Activities
MMSE
Mini Mental State Examination
NMDA
N-methyl-D-aspartate
PSA-NCAM
polysialylated form of the neural cell adhesion molecule


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 11 of 54
12 May 2016
CONFIDENTIAL
Abbreviation
Definition
PV
Pharmacovigilance
QTc
corrected QT (interval)
RBANS
Repeatable Battery for the Assessment of Neuropsychological Status
RBC
red blood cell
SAE
serious adverse event
SAP
Statistical Analysis Plan
SD
standard deviation
SMC
Safety Monitoring Committee
SOC
System Organ Class
TEAE
treatment-emergent adverse event
WBC
white blood cell
WCT
Worldwide Clinical Trials


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 12 of 54
12 May 2016
CONFIDENTIAL
2.
PROTOCOL SUMMARY
Study Title
A Long-Term, Open-Label Extension Study of the Safety and 
Tolerability of RVT-101 in Subjects with Alzheimer’s Disease
Objectives
Primary
To assess the long-term safety and tolerability of 35-mg 
RVT-101 in subjects with Alzheimer’s disease
Secondary
To assess the effects of RVT-101 on subject dependency as
measured by the Dependence Scale (DS) 
To assess the effects of RVT-101 on quality of life as 
measured by the EuroQOL 5 dimensions questionnaire (EQ-
5D)
Study Phase
Phase 3
Target Population
Subjects with Alzheimer’s disease who have completed the 24-week, 
double-blind, placebo-controlled, lead-in study RVT-101-3001.
Number of Subjects 
Planned
Maximum of 1150
Number of Study 
Centers Planned
Approximately 185
Study Design
This is a multi-center, open-label, extension study. The long term 
safety and tolerability of RVT-101 at a dose of 35 mg daily in a real-
world setting will be evaluated over a 12-month open-label treatment 
period in subjects who have completed the 24-week, double-blind,
placebo-controlled, lead-in study, RVT-101-3001.
Duration of Treatment
Study participation will last approximately 54 weeks:
An open-label treatment period of 52 weeks and a 2-week follow-up
period. 
An additional screening period of up to 4 weeks may apply to
subjects whose final on-treatment visit/V8 of lead-in study RVT-101-
3001 does not serve as V1 of this study.
Criteria for Evaluation
Safety evaluation: Adverse event (AE) recording, physical 
examinations, vital signs, electrocardiograms (ECGs), Columbia-
Suicide Severity Rating Scale (C-SSRS), and clinical laboratory 
assessments.
Tolerability: Premature discontinuations due to AEs.
Efficacy: Subject dependency will be measured by the DS. Quality of 
life will be assessed by the EQ-5D.
Statistical Methods
Safety: Data will be listed and tabulated by the treatment groups 
assigned in the lead-in study and by overall; descriptive statistics will 
be presented for all safety parameters. No inferential statistical 
analyses of safety parameters will be conducted.


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 13 of 54
12 May 2016
CONFIDENTIAL
Efficacy: DS and EQ-5D data will be listed and tabulated by the 
treatment groups assigned in the lead-in study and by overall; 
descriptive statistics will be presented. 


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 14 of 54
12 May 2016
CONFIDENTIAL
3.
INTRODUCTION
3.1.
Background
3.1.1.
Alzheimer’s Disease
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by 
deterioration of memory and other aspects of cognition, progressive impairment of activities of 
daily living, and a variety of behavioral disturbances (Cummings, 2004).  An estimated 5.2 million 
American’s have AD (Alzheimer’s Association, 2013).  In 2010, approximately 503,400 deaths in 
Americans aged 75 years and older were attributable to AD dementia (James et al, 2014), and the 
incidence is increasing as the global population ages (Cummings et al, 2014).  Between 2000 and 
2010, the proportion of deaths resulting from heart disease, stroke, and prostate cancer decreased 
16%, 23%, and 8%, respectively, whereas the proportion of deaths resulting from AD increased 
68% (Alzheimer’s Association, 2013).
The first drug specifically approved for the treatment of AD was tacrine, an acetylcholinesterase 
inhibitor.  Acetylcholinesterase inhibitors increase levels of acetylcholine, a key neurotransmitter 
for cognitive processes.  Although approved in many countries, tacrine was not widely used, most 
likely because it is associated with liver toxicity and because of an inconvenient dosing regimen.  
Soon after the approval of tacrine, donepezil, another acetylcholinesterase inhibitor, was approved 
and became the most widely used drug to treat AD, likely due to its lack of liver toxicity and once-
daily dose regimen (Aricept® [donepezil] Package Insert, 2013).  Two other acetylcholinesterase 
inhibitors were approved subsequently, resulting in a total of 4 marketed drugs of this class.  
Memantine, the only other drug approved for the treatment of AD, is an N-methyl-D-aspartate 
(NMDA) receptor antagonist and is only approved to treat moderate to severe AD.
Although the approved agents produce a modest improvement in cognition in the short term, they 
do not prevent progression of the disease, and patients continue to show decline in cognitive 
performance and inexorable progressive loss of function despite currently available treatments.  
There is a lack of treatment options available for patients once the initial effectiveness of the 
acetylcholinesterase inhibitor starts to wane, and there are no treatments currently approved for 
adjunct therapy to acetylcholinesterase inhibitors in subjects with mild to moderate AD.  No new 
chemical entities for AD have been approved in more than 10 years.  Thus, there is an urgent need 
to identify new drugs for the treatment of AD.
5-Hydroxytryptamine sub-type 6 (5HT6) receptors are widely distributed in regions of the brain 
that are associated with cognition.  5HT6 receptor antagonists have a modulatory effect on 
cholinergic, and other neurotransmitter systems, a profile that is clearly distinct from that of the 
acetylcholinesterase inhibitors (Mitchell and Neumaier, 2005).  In addition, 5HT6 receptor 
antagonists have been reported to cause increases in the polysialylated form of the neural cell 
adhesion molecule (PSA-NCAM) in the hippocampal and medial temporal regions of the brain 
during a learning task (Seki and Arai, 1993; Kiss et al, 2001).  PSA-NCAM increases have been 
correlated with increases in synaptic plasticity in areas such as the hypothalamus, olfactory bulb, 
and hippocampus of the adult nervous system (Seki and Arai, 1993; Kiss et al, 2001).


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 15 of 54
12 May 2016
CONFIDENTIAL
3.1.2.
RVT-101
RVT-101, previously known as SB742457, is a potent and selective 5HT6 receptor antagonist, 
which is being developed as an oral treatment for subjects with mild to moderate AD.
Pharmacology predicts central nervous system (CNS) effects on ACh for both donepezil and RVT-
101.  However, the mechanisms by which this is achieved by each treatment are clearly distinct.  
Donepezil exerts its effect by inhibiting acetylcholinesterase (AChE), thus inhibiting the hydrolysis 
of ACh, which results in increased ACh levels.  This can be associated with systemic cholinergic 
side effects, principally gastrointestinal in nature, but these events can be mitigated by slow 
titration.  RVT-101 causes a release of neurotransmitters primarily localized in the CNS through its 
antagonism at the 5HT6 receptor.  The potential increase in ACh following the addition of 
RVT-101 is expected to augment that already achieved with donepezil, and thus may result in an 
adjunctive treatment benefit (Benhamu et al, 2014).
RVT-101 has previously been investigated as monotherapy in subjects with mild to moderate AD 
in 3 multinational Phase 2 studies, Study AZ3100603, Study AZ3106242, and Study AZ3110865.  
Studies AZ100603 and Study AZ3110865 compared the efficacy of RVT-101 to placebo or 
donepezil on the co-primary endpoints of cognition (Alzheimer’s Disease Assessment Scale –
Cognitive Subscale [ADAS-Cog]) and global function (Clinician’s Interview-Based Impression of 
Change – plus caregiver interview [CIBIC+]) after 24 weeks of treatment.  Study AZ3100603 
demonstrated dose-related effects of RVT-101 on cognition (ADAS-Cog) with a 1.28-point 
treatment difference from placebo (p=0.135) at a dose of 35 mg and a statistically significant 
benefit on global function (CIBIC+) (p=0.047).  Of note, there was no evidence of a placebo 
decline in this study.  Study AZ3110865 did not show a statistically significant effect of either 
donepezil or RVT-101 on ADAS-Cog or CIBIC+.  This study also failed to show a decline in the 
placebo arm.
A third monotherapy study, AZ3106242, was initiated with the aim of investigating whether the 
historical efficacy of donepezil (i.e., approximately 3-point difference from a declining placebo 
group on ADAS-Cog after 24 weeks), could be repeated against non-declining placebo groups,
such as those seen in Studies AZ3100603 and AZ3110865.  It has become increasingly common in 
recent trials of potential agents for the treatment of AD to be unable to show the same 3-point 
difference from placebo on ADAS-Cog that was observed in these early studies with 
acetylcholinesterase inhibitors (Panisset, 2002).  In addition, the study allowed the effect of RVT-
101 to be benchmarked against a current, rather than historical, donepezil effect.  This exploratory 
study was not powered for formal statistical comparison of RVT-101 and donepezil.  For ADAS-
Cog and CIBIC+, neither RVT-101 nor donepezil showed a statistically significant difference from 
placebo.  A post-hoc analysis estimated that the effect of both treatments was larger among 
subjects with moderate AD (Mini Mental State Exam [MMSE] less than or equal to 18) than 
among mild subjects, with ADAS-Cog treatment effects of -2.9 (90% confidence interval [CI]: -
5.5, -0.2) and -4.5 (90% CI: -7.1, -1.9) for the RVT-101 and donepezil groups, respectively.
Study AZ3110866 was a 48-week, Phase 2b study that randomized 684 subjects in a 1:1:1 ratio to 
receive placebo, 15 mg RVT-101, or 35 mg RVT-101 as an adjunct to stable donepezil treatment.  
The study utilized co-primary cognitive endpoints at Week 24 (ADAS-Cog and Clinical Dementia 
Rating – Sum of Boxes [CDR-SB]).  The Alzheimer’s Disease Cooperative Study – Activities of 


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 16 of 54
12 May 2016
CONFIDENTIAL
Daily Living (ADCS-ADL) was also included as a secondary endpoint to assess the activities of 
daily living.  When compared to placebo, a statistically significant difference of 1.5 points in 
ADAS-Cog was observed for the 35-mg RVT-101 group versus the placebo group at Week 24 
(p=0.012).  Statistically significant benefit versus placebo was also demonstrated at Week 12 (-1.3,
p=0.006) and at Week 48 (-1.64, p=0.024).  There was a strong trend for statistically significant 
benefit at Week 36 (-1.21, p=0.057) versus placebo.  The change from baseline for the CDR-SB for 
the 35-mg group was numerically superior to placebo at all post-baseline visits.  This difference 
was statistically significant at Week 12. There were no statistically significant differences between 
the 15-mg group and placebo for either co-primary endpoint although the 15-mg group was 
generally numerically superior to placebo. The ADCS-ADL also showed a statistically significant 
effect for 35 mg RVT-101 compared to placebo at Weeks 12 (1.72, p=0.019), 24 (2.0, p=0.024), 
and 36 (1.93, p=0.038), with a continued trend at Week 48 (1.94, p=0.088).  Additional secondary 
endpoints included the Repeatable Battery for the Assessment of Neuropsychological Status 
(RBANS), and MMSE.  There was no statistically significant effect of RVT-101 on RBANS for 
either dose over placebo, but some degree of separation did appear at later visits for the 35-mg 
group.  No statistically significant difference for either group was seen on the MMSE at Weeks 24 
or 48.
Details of all the preclinical and clinical investigations with RVT-101 are contained in the current 
version of the RVT-101 Investigator’s Brochure.
3.2.
Study Rationale
The purpose of this study is to evaluate the long-term safety and tolerability of 35-mg RVT-101 in 
subjects with AD who have completed the lead-in study RVT-101-3001.
3.3.
Dose Rationale
The once-daily dose of 35 mg RVT-101 was selected for use in this study because it was used in 
the lead-in study RVT-101-3001 study. This dose, when administered in addition to stable 
donepezil treatment, was shown to be well tolerated and demonstrated efficacy on measures of 
cognition and activities of daily living that were statistically significant when compared to placebo 
treatment in study AZ3110866.


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 17 of 54
12 May 2016
CONFIDENTIAL
4.
OBJECTIVES AND ENDPOINTS
Objectives
Endpoints
Primary
To assess the long-term safety and tolerability of 
RVT-101
Incidence of AEs and changes in physical 
examinations, vital signs measurements, ECGs,
clinical laboratory assessments, and C-SSRS
results
Secondary
To assess the effects of RVT-101 on subject 
dependency as measured by the Dependence 
Scale (DS) 
DS score change from baseline at Weeks 28 and 
52
To assess the effects of RVT-101 on quality of 
life as measured by the EuroQOL 5 dimensions 
questionnaire (EQ-5D)
EQ-5D score change from baseline at Weeks 28 
and 52


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 18 of 54
12 May 2016
CONFIDENTIAL
5.
STUDY DESIGN
5.1.
Overall Design
This is a multi-center, open-label, extension study in subjects with AD who have completed the 24-
week, double-blind, placebo-controlled, lead-in study (RVT-101-3001). The long term safety and 
tolerability of RVT-101 at a dose of 35 mg daily in a real-world setting will be evaluated over a 12-
month open-label treatment period.
A maximum of 1150 subjects will be enrolled. Study participation will last approximately 54 
weeks: 52 weeks for the open-label treatment period and a 2-week follow-up period.  An additional 
screening period of up to 4 weeks may apply to subjects who choose not to combine V1 of this 
study with the last on-treatment visit/V8 of the lead-in study.
Subjects will be required to remain on donepezil at their current stable dose for at least the first 4 
weeks of this study; changes in donepezil dose and/or use of alternate background therapy during 
the first 4 weeks may be made only after approval by the Medical Monitor. After V2, a change in
subject’s dose of donepezil or transition to another background therapy will be acceptable if 
clinically warranted. RVT101 efficacy has been demonstrated in a previous study as an adjunctive 
therapy to donepezil and it is recommended that subjects remain on donepezil therapy throughout 
the course of the study. However, if the investigator or treating physician determines that a change 
in type or dose of background therapy is warranted after Visit 2, it will not be considered a protocol 
violation and subjects do not need to be discontinued from the study. Donepezil and other 
background therapies will be clinically prescribed by the investigator or treating physician and will 
not be supplied by the sponsor.
5.2.
Study Schematic
The design of the study is illustrated in Figure 1.


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 19 of 54
12 May 2016
CONFIDENTIAL
Figure 1.
Study Design
Open- Label Treatment
Screening/
Baseline
 V1
1
4WK
V2
 V3
 V4
28WK
52WK
Visit: 
Week:
40WK
RVT-101 35 mg qd
10WK
16WK
V5
V6
V7
Abbreviations: qd=daily; V=visit; WK=week
1V1 may be done at the same as, or within 4 weeks of, the last on-treatment visit of the lead-in study.
54WK
Safety 
Follow-up
 V8
0


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 20 of 54
12 May 2016
CONFIDENTIAL
6.
SUBJECT POPULATION
6.1.
Type and Number of Subjects
Subjects who have completed the double-blind lead-in study will be enrolled in this study. 
Enrollment in this study will be based on the completion rate of the lead-in study and is estimated 
to be no more than 1150 subjects.
6.2.
Inclusion Criteria
Subjects eligible for enrollment in the study must meet all of the following criteria:
1.
Male or female subjects who have completed the last on-treatment visit (V8) of lead-in 
study RVT-101-3001.
2.
Subject remains on donepezil at the current stable dose for at least the first 4 weeks of this 
study; changes in donepezil dose and/or use of alternate background therapy during the first 
4 weeks may be made only after approval by the Medical Monitor.
3.
Female subjects must be:
a. Of non-childbearing potential (i.e., any female who is post-menopausal [greater than 1 year 
without menstrual period in the absence of hormone replacement therapy]) or surgically 
sterile; or,
b. If pre-menopausal or menopausal for 1 year or less, must have a negative pregnancy test 
and must not be lactating at the Screening and Baseline Visits.  Female subjects of 
childbearing potential and who are sexually active are required to practice highly effective
methods of birth control during the course of the study and until the completion of the 
follow-up visit.  Female subjects for whom menopausal status is in doubt in the opinion of 
the Investigator will be required to use a highly effective form of birth control.  Highly 
effective forms of birth control are defined as methods that have a failure rate of less than 
1% per year when used correctly and consistently and include:
combined (estrogen and progestogen containing) hormonal contraception associated 
with inhibition of ovulation; oral, intravaginal, or transdermal
progestogen-only hormonal contraception associated with inhibition of ovulation; oral, 
injectable, or implantable
intrauterine device (IUD) 
intrauterine hormone-releasing system ( IUS) 
bilateral tubal occlusion 
vasectomised partner 
sexual abstinence
4.
Male subjects who are sexually active will be required to use an adequate form of birth 
control including at least 1 barrier method.


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 21 of 54
12 May 2016
CONFIDENTIAL
5.
Subject continues to be able to ingest pills (in tablet form) whole.
6.
Subject has provided full written informed consent prior to the performance of any 
protocol-specified procedure; or if unable to provide informed consent due to cognitive 
status, subject has provided assent and a legally acceptable representative has provided full 
written informed consent on behalf of the subject.
7.
Subject is able to comply with the study procedures in the opinion of the Investigator.
8.
General health status is acceptable for participation in this study.
9.
Subject lives with (or has substantial periods of contact with) a regular caregiver who is 
willing to attend Visits 1, 5, and 7 and report on subject’s status, and who has substantial 
contact with the subject.  If the caregiver does not cohabitate with the subject, he/she ideally 
should have a minimum of 10 hours total and at least 3 days contact with the subject per 
week.  Every effort should be made to have the same caregiver throughout the study.
10. Caregiver has provided full written informed consent, on a separate informed consent form,
on his/her own behalf prior to the performance of any protocol-specified procedure.
6.3.
Exclusion Criteria
A subject will be excluded from participation in this study if any of the following criteria apply:
1.
Subject experienced an uncontrolled AE in the lead-in study that would preclude 
continuation in a 12-month open label extension study, in the opinion of the Investigator.
Subjects who experienced an SAE during the lead-in study may be considered for 
participation in this study only after discussion with the Medical Monitor.
2.
Subject has a clinically significant vital signs or ECG abnormality at the end of the lead-in 
study, or at the Screening visit for this study, that would preclude continuation in a 12-
month open label extension study, in the opinion of the Investigator.
3.
Subject has a clinically significant laboratory abnormality at V7 or V8 of the lead-in study, 
or at the Screening visit for this study, that would preclude continuation in a 12-month open 
label extension study, in the opinion of the Investigator. Investigators need not wait for V8 
results before enrolling the subject in this study. However, any clinically significant 
abnormality subsequently identified from V8 of the lead-in study and/or at the Screening 
visit for this study will be evaluated by the Investigator for continued involvement in this 
study.
4.
Subject has developed any confounding medical or psychiatric condition that would 
preclude continuation in a 12-month open label extension study, in the opinion of the 
Investigator.
5.
Significant suicide risk as defined by suicidal ideation as endorsed on items 4 or 5 on the C-
SSRS at Screening of this study, or clinical assessment of significant suicidal risk.
6.
Treatment with any concomitant medication detailed in Table 1.
7.
females. Subjects with a QRS value greater than 120 msec and QTc value less than 


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 22 of 54
12 May 2016
CONFIDENTIAL
500 msec may be eligible following discussion with the Medical Monitor.
8.
Subject is unable to take the investigational product as prescribed throughout the 
study (with assistance is acceptable).
9.
Subject or caregiver is an immediate family member or employee of the participating 
investigator, any of the participating site staff, or of the sponsor study staff.


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 23 of 54
12 May 2016
CONFIDENTIAL
6.4.
Other Eligibility Criteria Considerations
To assess any potential impact on subject eligibility with regard to safety, the investigator
must refer to the RVT-101 Investigator’s Brochure for detailed information regarding 
warnings, precautions, contraindications, AEs, and other significant data pertaining to the 
investigational product being used in this study.
6.5.
Screening Failures
Screen failures are defined as subjects who sign an informed consent form (ICF) for 
RVT-101-3002 but do not receive any open-label treatment. Subjects who are Screen Failures 
may be rescreened once only after approval by the study Medical Monitor. The second screening 
visit must occur within 4 weeks of the original screening visit.
6.6.
Withdrawal Criteria
6.6.1.
Reasons for Withdrawal
A withdrawal from the study is defined as withdrawing any time after entering the open-label 
treatment period and before completion of the Week 52 Visit (Visit 7).  Subjects who 
permanently discontinue use of the investigational product will be considered to be withdrawn 
from the study.  Subjects may withdraw from the study at any time and for any reason.  The 
investigator (or designee) must document the reason for withdrawal in the electronic case report 
form (eCRF).  Information related to AEs will continue to be collected as per usual procedures 
for subjects who have discontinued the investigational product. Withdrawn subjects will not be 
replaced.  The reasons for subject withdrawal will be recorded and may include, but are not 
limited to:
Any clinical AE, laboratory abnormality, or other medical condition or situation occurs 
such that continued participation in the study would not be in the best interest of the 
subject in the opinion of the investigator
Pregnancy of female subject (discontinuation of treatment, but will be followed until the 
outcome of pregnancy is known)
Significant protocol violation
Subject requests to discontinue for any reason; it is important to determine whether the 
withdrawal of consent is primarily due to an AE, lack of efficacy, or other reason
The above reasons do not automatically lead to withdrawal from the study in all cases.  The final 
decision will be based on consultation between the principal investigator and the study Medical 
Monitor, with the ultimate decision by the principal investigator or subject.
If a subject meets discontinuation criteria during treatment, an Early Termination Visit will be 
required (Section 6.6.2).


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 24 of 54
12 May 2016
CONFIDENTIAL
6.6.2.
Subject Withdrawal Procedures
If a subject is prematurely discontinued from treatment with the investigational product, the 
investigator must make every effort to perform the evaluations scheduled for the Early 
Termination Visit (Table 2).  In the case where the subject permanently discontinues 
investigational product between scheduled clinic visits, he/she should be recalled to the clinic as 
soon as possible and preferably within 7 days of stopping the investigational product for the 
Early Termination Visit.
If a subject is lost to follow-up, every effort must be made by study center personnel to contact 
the subject, inquire about the reason for discontinuation, and follow up with any unresolved 
AEs/SAEs.  A minimum of 3 attempts at contact should be made with 1 contact being by 
certified letter.  All measures taken to contact the subject and information received during those 
attempts must be documented.


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 25 of 54
12 May 2016
CONFIDENTIAL
7.
STUDY TREATMENT
7.1.
Investigational Product and Other Study Treatment
Investigational product in this study is defined as RVT-101 tablets and will be provided by 
Axovant Sciences.  Investigational product will be supplied as single individual bottles, each 
bottle containing 50 tablets. One bottle of investigational product will be supplied at each of 
Visits 1, 2, and 3; two bottles will be dispensed at each of Visits 4, 5, and 6. This will be 
sufficient investigational product to cover the interval between visits, including the protocol-
allowed visit window, plus some overage.
Donepezil and other background therapies will be clinically prescribed by the Investigator or 
treating physician and will not be supplied by the sponsor.
Characteristic
Investigational Product
Product Name:
RVT-101
Formulation Description:
Pink film-coated round tablets
Dosage Form:
35-mg tablet
Unit Dose Strength(s)/
Dosage Level(s):
35 mg/
35 mg
Route of Administration:
Duration (Treatment Period):
Oral
52 weeks
Dosing Instructions:
Take 1 tablet orally each morning without regard to food
Manufacturer/Source of 
Procurement
Catalent Pharma Solutions, Kansas City, MO USA
7.2.
Randomization/Treatment Assignment
This is an open-label study and no randomization of treatment assignment will occur. Subjects 
who are enrolled in this study will receive RVT-101 35-mg tablets.
7.3.
Blinding
This is an open-label study; no blinding of treatments will occur.
7.4.
Packaging and Labeling
RVT-101 35-mg tablets will be packaged in 50-count, high-density polyethylene bottles.  Labels 
for RVT-101 bottles will meet all applicable requirements of the US Food and Drug 
Administration (FDA), EU Commission Directive 2003/94/EC, Eudralex Volume 10 ANNEX


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 26 of 54
12 May 2016
CONFIDENTIAL
13-Good Manufacturing Practice for the manufacture of investigational medicinal products (July 
2010), and/or other local regulations as applicable.
The label for the investigational product will contain at a minimum the following information for 
the US (additional items may be added as required for other countries):
Protocol number
Lot number
Bottle identification number
Quantity
Dosing directions
“Caution: New Drug – Limited by Federal law to investigational use. Keep out of reach 
of children.”
7.5.
Preparation/Handling/Storage/Accountability
No special preparation of investigational product is required.  Investigational product will be 
stored at room temperature (15- 30°C) and protected from light.
Only subjects enrolled in the study may receive investigational product and only 
authorized site staff may supply or administer investigational product.  All investigational 
product must be stored in a secure, environmentally controlled and monitored (manual or 
automated) area in accordance with the labelled storage conditions, with access limited to 
the investigator and authorized site staff.
The investigator, institution, or the head of the medical institution (where applicable), is 
responsible for investigational product accountability, reconciliation, and record 
maintenance (i.e., receipt, reconciliation, and final disposition records).
Site staff will record the subject number on the packaging label for the investigational 
product for each bottle dispensed. 
Under normal conditions of handling and administration, investigational product is not 
expected to pose significant safety risks to site staff.  In the case of unintentional 
occupational exposure, notify the Medical Monitor and/or the Axovant Sciences study 
contact.
A Material Safety Data Sheet/equivalent document describing occupational hazards and 
recommended handling precautions will be provided to the investigator where this is 
required by local laws, or will be available upon request from Axovant Sciences.
Unused investigational product will be reconciled and returned to the sponsor upon
notification by the sponsor or sponsor representative. The instructions and address for 
returning unused investigational product will be provided in a separate document.


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 27 of 54
12 May 2016
CONFIDENTIAL
7.6.
Compliance with Investigational Product Administration
Every effort should be made to encourage subject compliance with the dosage regimen as per 
protocol for investigational product.  The investigator is responsible for discussing with subjects
methods to ensure high treatment compliance.  All subjects should be instructed to return 
investigational product bottles with any unused drug at each visit to the investigator.  A record of 
the supplies dispensed, taken, and returned at each visit will be made in the source documents 
and eCRF.  For each bottle, the investigator or designee is responsible for reconciling the number 
of tablets returned with the expected number of tablets taken and accounting for any 
discrepancies.
Subjects should be withdrawn from the study if they have demonstrated significant non-
compliance with investigational product administration without acceptable explanation, in the 
opinion of the Investigator and after discussion with the Medical Monitor. While interruptions in 
investigational product administration should be avoided wherever possible, short-term 
interruptions due to forgetfulness; caregiver illness or absence; a pause in investigational product
administration required during an intervention, hospitalization, or while a subject considers the 
study continuation; or for any other reason are not grounds for automatic withdrawal but should 
be assessed by the investigator.
Other major protocol violations as well as use of prohibited drugs (see Section 7.9.2) may be 
cause for discontinuation of investigational product or withdrawal from the study.
Decisions regarding dose interruptions will be made by the investigator in consultation with the 
Medical Monitor based on the clinical evaluation of the subject.
7.7.
Treatment of Investigational Product Overdose
Any dose of RVT-101 greater than 100 mg within a 24-hour time period will be considered an 
overdose.
No data are available with regard to overdose of RVT-101 in humans.  There is no specific 
treatment to be used in the event of overdose with RVT-101.  Investigators should use their 
clinical judgment in treating cases of overdose as dictated by the subject’s clinical status.
In the event of an overdose the investigator or treating physician should:
Contact the Medical Monitor immediately,
Closely monitor the subject for AEs/SAEs and laboratory abnormalities and ensure 
appropriate clinical management. Overdose in the absence of other AEs will not be reported 
as an AE in its own right.
Document the quantity of the excess dose as well as the time of administration of the 
overdose in the eCRF.


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 28 of 54
12 May 2016
CONFIDENTIAL
7.8.
Treatment after the End of the Study
The investigator is responsible for ensuring that consideration has been given to the post-study 
care of the subject’s medical condition.
7.9.
Concomitant Medications and Non-Drug Therapies
7.9.1.
Permitted Medications and Non-Drug Therapies
All current concomitant medications, including over-the-counter and herbal remedies, will be 
recorded in the eCRF. Current non-medication therapies related to the subject’s AD 
(neurostimulation, cognitive rehabilitation) must also be recorded.  Changes to concomitant 
medications or non-medication therapies throughout the study must also be recorded. The name 
of the drug, the dose, indication and route of administration as well as the dates administered 
should be documented; the minimum requirement is to record the drug name and dates of 
administration.  Any medication not specified in the list of prohibited medications provided in 
Table 1 is permitted during the study.
Subjects will be required to remain on donepezil at their current stable dose for at least the first 4 
weeks of this study; changes in donepezil dose and/or use of alternate background therapy during 
the first 4 weeks may be made only after approval by the Medical Monitor. After V2, a change in 
subject’s dose of donepezil or transition to another background therapy will be acceptable if 
clinically warranted. RVT101 efficacy has been demonstrated in a previous study as an 
adjunctive therapy to donepezil and it is recommended that subjects remain on donepezil therapy 
throughout the course of the study. However, if the investigator or treating physician determines 
that a change in type or dose of background therapy is warranted after Visit 2, it will not be 
considered a protocol violation and subjects do not need to be discontinued from the study. 
Donepezil and other background therapies will be clinically prescribed by the Investigator or 
treating physician and will not be supplied by the sponsor. The background therapy name, dose, 
route of administration, administration dates, and any changes should be recorded in the 
concomitant medication eCRF. 
Subjects may begin to concomitantly use memantine or other medications used to treat dementia 
or other cognitive impairments after Visit 2, as long as the medication is not specified in the list 
of prohibited medications provided in Table 1. The use of memantine (including dose,
administration dates, and any changes) should be recorded in the concomitant medication eCRF. 
7.9.2.
Prohibited Medications and Non-Drug Therapies
Subjects who take any prohibited medication during the study should be withdrawn from the 
study.  However, in some situations in which a prohibited medication is required for a limited 
period of time, investigational product may be discontinued during the treatment of the 
prohibited medication and restarted after the termination of the prohibited medication, if 
considered appropriate by the investigator and with prior discussion with the Medical Monitor, 
based on subject safety and the perceived need for the prohibited treatment.  Use of prohibited 


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 29 of 54
12 May 2016
CONFIDENTIAL
medications must be documented in the Concomitant Medications section of the eCRF.
Prohibited medications are listed in Table 1.


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 30 of 54
12 May 2016
CONFIDENTIAL
Table 1.
List of Prohibited Medications
Prohibited Medications:
Not allowed during the 
study or within 5 half-lives 
prior to V1/Screening
Selegiline
Butyrophenones,
phenothiazines, and other
“conventional”
antipsychotics
Barbiturates
MAO inhibitors
Any investigational drug
Substrates of CYP2C91 with narrow 
therapeutic indices: warfarin, phenytoin and 
(R)-acenocoumarol (active component of 
some non-warfarin anticoagulants)
Potent CYP3A42 inhibitors/inducers such as 
ketoconazole, itraconazole, erythromycin, 
rifampicin, phenytoin and carbamazepine
Known potent P-gp inhibitors3 (itraconazole, 
ketoconazole, cyclosporin, diltiazem,
verapamil, quinidine, and
carvedilol)
Abbreviations:  MAO = monoamine oxidase; Pgp = permeability glycoprotein
Notes: 
1RVT-101 affects CYP2C9 substrates.
2CYP3A4 is a major enzyme involved with the metabolism of RVT-101.
3Pgp inhibition may affect CNS levels of RVT-101.
7.10.
Lifestyle and/or Dietary Restrictions
7.10.1.
Meals and Dietary Restrictions
Subjects should refrain from consumption of grapefruit or grapefruit juice due to the potential to 
raise RVT-101 concentrations.


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 31 of 54
12 May 2016
CONFIDENTIAL
8.
STUDY ASSESSMENTS AND PROCEDURES
Protocol waivers or exemptions are not allowed, with the exception of immediate safety 
concerns. Therefore, adherence to the study design requirements, including those specified 
in the Time and Events Table, are essential and required for study conduct.
8.1.
Time and Events
The Time and Events Schedule (Table 2) displays each study assessment and procedure along 
with the time of occurrence.  V1 of this study may be combined with the final on-treatment visit, 
V8, of lead-in study RVT-101-3001, or be conducted within 4 weeks of that visit. V2 will occur 
approximately 4 weeks after V1; V3 and V4 will each occur approximately 6 weeks after the 
previous visit; subsequent visits will occur approximately every 3 months thereafter. In the event 
of spontaneously reported tolerability problems, an unscheduled visit will be arranged to assess
the subject. 
All study assessments should be conducted by the investigator, and/or a suitably qualified 
designee approved and documented for this study. Information for each visit will be recorded in 
the source documents and, where appropriate, the eCRF.
V1/Screening/Baseline: The final on-treatment visit, V8, of lead-in study RVT-101-3001 may 
serve as V1 of this study. If V1 of this study occurs at the same time or within 7 days of V8 of 
the lead-in study RVT-101-3001, then the procedures conducted for V8 of the lead-in study
RVT-101-3001 may serve as the procedures required for V1 of this study and need not be 
repeated. If V1 of this study occurs greater than 7 days after V8 of the lead-in study RVT-101-
3001, then all procedures specified for V1 of this study must be repeated and cannot be 
combined with the procedures performed on V8 of the lead-in study RVT-101-3001. V1 of this 
study must occur within 4 weeks of V8 of the lead-in study.
An ICF will be signed by each subject, if he or she is able, or by the subject’s legally authorized 
representative with subject assent before any study-specific procedures are performed. An ICF 
will also be signed by the caregiver before any study-specific procedures are performed.
Subjects will be screened for eligibility according to study inclusion/exclusion criteria at this 
visit. Eligible subjects will be dispensed investigational product and will be instructed to take it
once daily in the morning with or without food.
Subjects who do not qualify for the study during this visit will be considered Screen Failures,
and may be rescreened (only once) after discussion with the Medical Monitor. The repeat 
screening visit must occur within 4 weeks of the original screening visit.
Open-Label Treatment Period (V2 through V7): Visits 2 through 7 should be scheduled 
relative to V1 with a visit window of ± 7 days. If the visit window is used, the subsequent visit 
should remain according to the planned visit schedule (i.e., the subsequent visit date should not 
be re-calculated from the date of the previous visit but should remain relative to baseline).


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 32 of 54
12 May 2016
CONFIDENTIAL
Investigational product compliance will be performed on returned study bottles, and new bottles 
of investigational product will be dispensed, at each visit. Subjects will be reminded to take the 
investigational product once daily in the morning with or without food.
Subjects who prematurely discontinue from the open-label treatment period will be required to 
attend a safety clinic visit, preferably within 7 days of stopping the investigational product, and 
perform the procedures indicated for the V7/Early Termination (ET) Visit.
Follow-Up Visit (V8): All subjects who complete the open-label treatment period will be
contacted by phone 14 to 19 days after the last dose of investigational product is taken to assess 
for any new AEs and follow-up on any open AEs. The Investigator may choose to conduct this 
visit in the clinic and may perform additional assessments if results of any of the V7 evaluations 
are considered clinically significant.


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 33 of 54
12 May 2016
CONFIDENTIAL
Table 2.
Time and Events Schedule
Study Period:
Screening
and 
Baseline
Open-Label Treatment Period
Follow-
up
Unscheduledb
Study Visit Number:
V1a
V2
V3
V4
V5
V6
V7/ET
V8
UNS
Study Week:
W0
W4
W10
W16
W28
W40
W52
W54
UNS
Study Day:
relative to Baseline 
unless specified
0
28 ± 7
70 ± 7
112 ± 7
196 ± 7
280 ± 7
364 ± 7
14 to 19 
days after 
last dose of 
IP 
UNS
Informed consent
X
Inclusion and exclusion criteria
X
Demography, standard medical 
history
Xc
Targeted medical history d
X
Prescription for donepezil e
X
Concomitant medications review
Xc
X
X
X
X
X
X
X
Urine Drug screen
X
Xf
X
C-SSRS
X
X
X
X
X
X
X
X
Dispense IP
X
X
X
X
X
X
Assess IP compliance
X
X
X
X
X
X
X
Physical exam
X
X
X
X
Neurological exam
X
X
X
X
12-lead ECG
X
X
X
X
Vital signs g
X
X
X
X
X
X
X
X
Review AEs
X
X
X
X
X
X
X
X


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 34 of 54
12 May 2016
CONFIDENTIAL
Study Period:
Screening
and 
Baseline
Open-Label Treatment Period
Follow-
up
Unscheduledb
Study Visit Number:
V1a
V2
V3
V4
V5
V6
V7/ET
V8
UNS
Study Week:
W0
W4
W10
W16
W28
W40
W52
W54
UNS
Study Day:
relative to Baseline 
unless specified
0
28 ± 7
70 ± 7
112 ± 7
196 ± 7
280 ± 7
364 ± 7
14 to 19 
days after 
last dose of 
IP 
UNS
Serum chemistry, Hematology,
Urinalysis
X
X
X
X
X
X
X
X
Serum or urine pregnancy test h
X
X
X
DS
X
X
X
EQ-5D
X
X
X
Telephone Visit
X
Abbreviations:  AE=Adverse event; C-SSRS = Columbia Suicide Severity Rating Scale; DS= Dependence Scale; ECG = electrocardiogram; EQ-5D= EuroQOL 
5 dimensions questionnaire; ET = early termination; IP=investigational product; UNS= unscheduled; V = visit; W = week.
Notes: 
a) The final on-treatment visit, V8, of lead-in study RVT-101-3001 may serve as V1 of this study. If V1 of this study occurs greater than 7 days after V8 of the 
lead-in study, then all procedures specified for V1 of this study must be repeated and cannot be combined with the procedures performed on V8 of the lead-in 
study. V1 of this study must occur within 4 weeks of V8 of the lead-in study.
b) Unscheduled visits and/or assessments to occur at the discretion of the Investigator.
c) Data for demography, standard medical history, and concomitant medications review at Screening will be rolled over from lead-in study RVT-101-3001.
d) Targeted medical history will consist only of ongoing medical conditions and open AEs from the lead-in study, if any.
e) Clinical prescription for donepezil will be provided by the Investigator or the treating physician.
f) For ET visit only.
g) Vital signs will include systolic and diastolic blood pressure, pulse rate, respiratory rate, temperature, and body weight at each visit; height will be performed 
at screening only.
h) Pregnancy test required only for women of child-bearing potential.


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 35 of 54
12 May 2016
CONFIDENTIAL
8.2.
Study Assessments and Procedures
8.2.1.
Safety and Screening Assessments
8.2.1.1.
Adverse Events
The investigator or site staff is responsible for detecting, documenting, and reporting events that 
meet the definition of an AE or SAE.
8.2.1.1.1.
Definition of Adverse Events
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether 
or not considered drug related.  Therefore an AE can be ANY unfavorable and unintended sign 
(including an abnormal laboratory finding or vital sign measurement), symptom, or disease 
temporally associated with the use of a medicinal product, without any judgment about causality.
AEs are recorded from the time that informed consent is signed. Treatment emergent AEs are 
defined as those that occur on or after the date of the first dose of investigational product.
Events meeting the definition of an AE include:
Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency and/or intensity of the condition.
New conditions detected or diagnosed after investigational product administration even 
though it may have been present prior to the start of the study.
Signs, symptoms, or the clinical sequelae of a suspected drug interaction.
Signs, symptoms, or the clinical sequelae of a suspected overdose of either 
investigational product or a concomitant medication.
Clinically significant abnormal findings (laboratory test results, vital signs, physical 
examination findings, ECGs, radiologic exams, or other studies) should be recorded as 
AEs. A “clinically significant” finding is one that affects clinical management, including
additional visits, monitoring or referrals, diagnostic tests or alteration of treatment, or that 
is considered clinically significant by the investigator.  A clinically significant finding 
may be a change in a test that has previously been abnormal but now requires additional 
action.
When a medical or surgical procedure is performed, the condition that leads to the 
procedure should be recorded as the AE.
Events that do not meet the definition of an AE include:
Anticipated day-to-day fluctuations or expected progression of pre-existing disease(s) or 
condition(s) present or detected at the start of the study unless judged by an investigator 
to be more severe than expected for the subject’s underlying condition.
Abnormal laboratory, ECG, or vital sign measurements that are not labelled clinically 
significant (see definition above).


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 36 of 54
12 May 2016
CONFIDENTIAL
Situations where an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).
Overdose in the absence of other AEs will not be reported as an AE in its own right.
Changes in C-SSRS during the course of the study indicating worsening should be 
evaluated by the investigator for clinical significance, and if clinically significant (e.g., 
alteration in medical care or intervention is required), an associated AE should be 
recorded, if present.  The AE should be the primary underlying clinical manifestation 
assessed as clinically significant, and not the change in score itself.
8.2.1.1.2.
Definition of Serious Adverse Event
An AE is considered serious if, in the view of either investigator or sponsor, it results in any of 
the following outcomes:
Death,
A life-threatening AE, 
(An AE is considered “life-threatening” if, in the view of either the investigator or 
sponsor, its occurrence places the subject at immediate risk of death.  It does not include 
an AE that, had it occurred in a more severe form, might have caused death.  The
determination of whether an AE is life-threatening can be based on the opinion of either 
the investigator or sponsor.  Thus, if either believes that it meets the definition of life-
threatening, it must be considered life-threatening for reporting purposes.)
Inpatient hospitalization or prolongation of existing hospitalization,
A persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions, or
A congenital anomaly/birth defect.
Important medical events that may not result in death, be life-threatening, or require 
hospitalization may be considered serious when, based upon appropriate medical 
judgment, they may jeopardize the patient or subject and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition.  Examples of such 
medical events include allergic bronchospasm requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in 
inpatient hospitalization, or the development of drug dependency or drug abuse.
This definition of an SAE permits either the sponsor or the investigator to decide if an event is 
serious.  Because SAEs are critically important for the identification of significant safety 
problems, FDA believes taking into account both the investigator’s and the sponsor’s assessment 
is important.  For example, the investigator’s perspective may be informed by having actually 
observed the event, and the sponsor is likely to have broader knowledge of the drug and its 
effects to inform its evaluation of the significance of the event.  If either the sponsor or 
investigator believes that the event is serious, the event must be considered serious and evaluated 
by the sponsor for possible expedited reporting.


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 37 of 54
12 May 2016
CONFIDENTIAL
8.2.1.1.3.
Time Period and Frequency for Collecting Adverse Event and Serious Adverse 
Event Information
Collection of AEs and SAEs will begin at the time a subject signs informed consent and 
continues until the follow-up visit. SAEs that are spontaneously reported by the subject or 
subject representative or discovered by the investigator or designee after the follow-up visit and 
up to 30 days after the last dose of investigational product must be collected and reported.
All SAEs will be recorded and reported to Worldwide Clinical Trials or Axovant Sciences within 
24 hours of the investigator becoming aware of the SAE according to Section 8.2.1.1.7.
Investigators are not obligated to actively seek AEs or SAEs in former study subjects.  However, 
if the investigator learns of any SAE, including a death, at any time after a subject has been 
discharged from the study, and he/she considers the event reasonably related to the 
investigational product or study participation, the investigator must promptly notify the sponsor 
or sponsor representative.
8.2.1.1.4.
Assessment of Adverse Events
The severity of each AE will be assessed by the investigator, or designee approved and 
documented for this study, as mild, moderate, or severe based on the below definitions:
Mild: Event that is usually transient and may require only minimal treatment or 
therapeutic intervention.  The event does not generally interfere with usual activities of 
daily living.
Moderate: Event that is usually alleviated with additional specific therapeutic 
intervention.  The event interferes with usual activities of daily living, causing 
discomfort, but poses no significant or permanent risk of harm to the subject.
Severe: Event that interrupts usual activities of daily living or significantly affects clinical 
status, or may require intensive therapeutic intervention.
Note that severity is not the same as “seriousness,” which is defined in Section 8.2.1.1.2.
Outcome will be assessed using the following categories: recovered/resolved, not recovered/not 
resolved, recovered/resolved with sequelae, fatal, or unknown.
Causality with respect to investigational product will be assessed as follows:
Certain: 
o
An event or laboratory test abnormality, with plausible time relationship to drug 
intake 
o
Cannot be explained by disease or other drugs
o
Response to withdrawal plausible (pharmacologically, pathologically) 
o
Event definitive pharmacologically or phenomenologically (ie, an objective and 
specific medical disorder or a recognized pharmacological phenomenon) 
o
Rechallenge satisfactory, if necessary 
Probable:


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 38 of 54
12 May 2016
CONFIDENTIAL
o
An event or laboratory test abnormality, with reasonable time relationship to drug 
intake 
o
Unlikely to be attributed to disease or other drugs 
o
Response to withdrawal clinically reasonable 
o
Rechallenge not required 
Possible: 
o
An event or laboratory test abnormality, with reasonable time relationship to drug 
intake 
o
Could also be explained by disease or other drugs 
o
Information on drug withdrawal may be lacking or unclear 
Unlikely: 
o
An event or laboratory test abnormality, with a time to drug intake that makes a 
relationship improbable (but not impossible) 
o
Disease or other drugs provide plausible explanations 
Not Related:
o
An event or laboratory test abnormality, with a time to drug intake that makes a
relationship impossible 
o
Disease or other drugs provide definitive explanations 
8.2.1.1.5.
Method of Detecting Adverse Events and Serious Adverse Events
Care will be taken not to introduce bias when detecting AEs and/or SAEs.  Open-ended and 
non-leading verbal questioning is the preferred method to inquire about AE occurrence.  
Appropriate questions include:
“How are you feeling?”
“Have you had any (other) medical problems since your last visit/contact?”
“Have you taken any new medicines, other than those provided in this study, since your last 
visit/contact?”
8.2.1.1.6.
Follow-up of Adverse Events and Serious Adverse Events
After the initial AE/SAE report, the investigator is required to proactively follow each subject at 
subsequent visits/contacts.  All AEs and SAEs will be followed until resolution, until the 
condition stabilizes, until the event is otherwise explained, or until the subject is lost to follow-up
(according to Section 6.6.2).


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 39 of 54
12 May 2016
CONFIDENTIAL
8.2.1.1.7.
Reporting of Serious Adverse Events
All SAEs and deaths, regardless of relationship to the study procedures or investigational product,
must be reported in English to the study sponsor or sponsor’s representatives within 24 hours of 
the investigators first knowledge of the event through data entry in the SAE eCRF via the electronic 
data capture (EDC) system. In the event that the EDC system is unavailable, the paper SAE Report 
form should be used and emailed to Worldwide Clinical Trials Pharmacovigilance (WCT PV) at 
the following address:  
drugsafety@wwctrials.com
In the event that email reporting is not available, site personnel should fax the SAE report to:
fax number: +44 (0)115 922 0960
If notification is made via email or fax, site personnel must then enter the SAE information into 
the EDC system as soon as the system becomes available. 
For the initial SAE notification report, the investigator must provide, at minimum, basic 
information such as the protocol number, subject’s date of birth, subject identification number, 
period of investigational product intake, event term, nature of the event, the seriousness criteria, 
and the investigator’s attribution regarding relatedness to investigational product.  The initial 
SAE report should include all pertinent known information about the SAE and the affected 
subject.  In addition, the investigator should provide a narrative to describe the course of events 
including any treatments or relevant procedures.  If requested by WCT PV, any missing or 
additional relevant information concerning the SAE should be entered into the EDC or 
emailed/faxed to WCT PV.   
Follow-up SAE reports may describe the evolution of the reported event and any new assessment 
of outcome and/or relationship to investigational product.  Full supporting documentation should 
be solicited by the investigative site even if the SAE occurred at another institution.  Such 
documentation may include copies of relevant medical/hospital records, pathology, or autopsy 
reports.
8.2.1.1.8.
Regulatory Reporting Requirements for Serious Adverse Events
Prompt notification by the investigator to the sponsor or sponsor representative of all SAEs and 
non-serious AEs occurring during a clinical trial is essential so that legal obligations and ethical 
responsibilities towards the safety of subjects and the safety of a product under clinical 
investigation are met.
Axovant Sciences has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a product under clinical investigation.  Axovant Sciences
will comply with country-specific regulatory requirements relating to safety reporting to the 
regulatory authority, Institutional Review Board (IRB)/Independent Ethics Committee (IEC) and 
investigators.


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 40 of 54
12 May 2016
CONFIDENTIAL
Investigator safety reports are prepared for suspected unexpected serious adverse reactions (those 
not listed in the Investigator Brochure) according to local regulatory requirements and Axovant 
Sciences policy and are forwarded to investigators as necessary.
An investigator who receives an investigator safety report describing an SAE(s) or other specific 
safety information (e.g., summary or listing of SAEs) from Axovant Sciences will file it with the 
Investigator Brochure and will notify the IRB/IEC, if appropriate according to local 
requirements.
8.2.1.2.
Safety Monitoring Committee
An independent Safety Monitoring Committee (SMC) will be established by the sponsor to 
review accumulating study data to monitor the safety of all subjects enrolled in RVT-101-3002
on an ongoing basis.  Members of the committee will include clinicians and a biostatistician who 
are experienced in the conduct and monitoring of clinical studies.  No Axovant Sciences 
employee or investigator involved in the study will be a member of the SMC or participate in 
closed SMC sessions.  However, representatives from Axovant Sciences may attend open 
meeting sessions and will be available to provide additional information to the SMC as 
requested.
The SMC will evaluate potential safety and tolerability issues during periodic scheduled reviews 
of the safety data accrued during the conduct of the study.  The content and format of the safety 
data provided will be in agreement with requests by the SMC members. Ad hoc SMC meetings 
may be held as necessary.
After reviewing the interim safety data, the SMC may make a recommendation to Axovant 
Sciences to continue the study with or without modification or to terminate the study.  All SMC
meetings will be properly documented in a SMC report to the sponsor.
SMC membership and responsibilities will be further outlined in the SMC Charter, which will be 
maintained separately from the protocol.
8.2.1.3.
Physical and Neurological Examinations
Physical and neurological examinations will be performed as indicated in Table 2. Physical 
examinations will include, at a minimum, assessment of the cardiovascular, respiratory, 
gastrointestinal, and neurological systems.  Neurological examinations will include assessment 
of gait, balance, coordination, cranial nerves and motor and sensory systems.
8.2.1.4.
Vital Signs
Vital signs will be measured after the subject has been in the seated position for 5 minutes and 
will include systolic and diastolic blood pressures, pulse rate, respiratory rate, temperature, and 
body weight at each visit; height will be recorded at Screening only.
8.2.1.5.
Electrocardiogram
Single 12-lead ECGs will be obtained using an ECG machine that automatically calculates the 
heart rate and measures PR, QRS, QT, and QTc intervals with the subject in the supine position.  
The investigator or designated qualified physician at the site will evaluate the Screening ECG for 


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 41 of 54
12 May 2016
CONFIDENTIAL
any abnormalities that should exclude the subject from the study or require acute additional 
evaluation or intervention.  They should also evaluate the ECG printouts for subsequent visits for 
any new abnormalities.  Any abnormality should include a determination of clinical significance.  
A clinically significant ECG finding is one that requires additional medical evaluation or 
treatment.
8.2.1.6.
Clinical Safety Laboratory Assessments
All protocol-required laboratory assessments, as defined in Table 3, must be conducted in 
accordance with the central Laboratory Manual and Time and Events Schedule (Table 2).
Laboratory requisition forms must be completed and samples must be clearly labelled with the 
subject number, protocol number, site/center number, and visit date.  Details for the preparation 
and shipment of samples will be provided by the laboratory and are detailed in the central
Laboratory Manual.  Reference ranges for all safety parameters will be provided to the 
investigator by the laboratory responsible for the assessments.
Abnormal laboratory test results that are clinically significant should be recorded as AEs on the 
eCRF.  Clinically significant means that the confirmed abnormal test result has an impact on 
subject management, including additional monitoring or diagnostic tests, or changes in treatment.
The same standard applies to additional non-protocol specified laboratory assessments that are 
performed at the institution’s local laboratory and result in a change in subject management (ie, 
monitoring, diagnostic tests, or any alteration in treatment).
Refer to the central Laboratory Manual for appropriate processing and handling of samples to 
avoid duplicate and/or additional blood draws.
Hematology, clinical chemistry, urinalysis, and other screening laboratory parameters to be 
tested are listed in Table 3.
Table 3.
Protocol-Required Screening and Safety Laboratory Assessments
Laboratory 
Assessments
Parameters
Hematology
Platelet count
RBC count
Hemoglobin
Hematocrit
RBC Indices
MCV
MCH
WBC Count with Differential
Neutrophils
Lymphocytes
Monocytes
Eosinophils
Basophils
Clinical 
Chemistry
BUN
Creatinine
Glucose
Potassium
Sodium
Calcium
Chloride
Bicarbonate
AST
ALT
Alkaline phosphatase
Total and direct 
bilirubin
Total protein


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 42 of 54
12 May 2016
CONFIDENTIAL
Albumin
GGT
Routine 
Urinalysis
Specific gravity
pH, glucose, protein, blood, and ketones by dipstick
Microscopic examination (if blood or protein is abnormal)
Additional 
Tests
Drug screen
Serum or urine hCG pregnancy test (for women of child-bearing potential)
Abbreviations:  ALT = alanine aminotransferase; AST = aspartate aminotransferase; BUN = blood urea nitrogen; 
eGFR estimated glomerular filtration rate; GGT = gamma glutamyltransferase; hCG = human chorionic 
gonadotropin; MCH = mean corpuscular hemoglobin; MCV = mean corpuscular volume; RBC = red blood cell;
WBC = white blood cell.
All laboratory tests with values that are considered clinically significantly abnormal during 
participation in the study or at the follow-up visit should be repeated until the values return to 
normal or baseline or until the value stabilizes.  If such values do not return to normal within a 
period judged reasonable by the investigator, the etiology should be identified and the Medical 
Monitor notified.
8.2.1.7.
Assessment of Suicidality
Subjects will be assessed for suicidality before and during the study using the Columbia Suicide 
Severity Rating Scale (C-SSRS).  Subjects considered to be at significant risk will be excluded 
from the study.  The C-SSRS is a brief measure which is designed to assess severity and change 
of suicidality by integrating both behavior and ideation.  It assesses intensity of ideation (a 
potentially important marker of severity), specifically asking about frequency, duration, 
controllability, deterrents, and reasons for the ideation which was most severe during the 
respectively assessed timeframe.  Suicidal behavior is also assessed by asking further questions 
to categorize the behaviors into actual, interrupted, or aborted attempts; as well as preparatory 
and non-suicidal self-injurious behavior.  The C-SSRS will be completed by a rater who is 
trained and certified to administer this scale.  Any change in C-SSRS score indicating the 
presence of suicidality should be evaluated by the investigator for clinical significance to 
determine continued study eligibility (Section 6.3) and appropriate clinical actions (including but 
not limited to a referral to a mental health professional).
Clinically meaningful suicidal ideation, suicidal behavior, and completed suicide should be 
recorded as AEs or SAEs.
8.2.1.8.
Pregnancy
Details of all pregnancies in female subjects will be collected after the start of dosing and until 
30 days after the last dose of investigational product. 
Pregnancies are to be reported by the Investigator within 24 hours of the site’s awareness by 
completing the Pregnancy Notification Form and emailing it to WCT PV at the following 
address: 
drugsafety@wwctrials.com


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 43 of 54
12 May 2016
CONFIDENTIAL
In the event that email reporting is not available, site personnel should fax the Pregnancy report 
to:
fax number: +44 (0)115 922 0960
The pregnancy must be followed up to determine outcome (including premature termination) and 
status of mother and child.  Pregnancy complications or elective terminations for medical reasons 
must be reported as an AE or SAE.  Spontaneous abortions, birth defects, and congenital 
anomalies must be reported as SAEs.
Any SAE occurring in association with a pregnancy brought to the investigator’s attention after 
the subject has completed the study and considered by the investigator as possibly related to the 
investigational product must be promptly reported to the sponsor or the sponsor’s representative.
The investigator must attempt to collect pregnancy information on any female partners of male 
study subjects who become pregnant while the subject is enrolled in the study.  Pregnancy 
information must be reported to the sponsor or the sponsor’s representative as described above.  
The partner will also be followed to determine the outcome of the pregnancy.  Information on the 
status of the mother and child will be forwarded to the sponsor or the sponsor’s representative. 
Generally, follow-up will be no longer than 6 to 8 weeks following the estimated delivery date.  
Any premature termination of the pregnancy will be reported.
8.2.2.
Efficacy Assessments
8.2.2.1.
Dependence Scale
The DS measures the amount of assistance patients with dementia require in performing daily 
activities.  The caregiver answers questions about the dependency of the subject.  The scale 
consists of 13 items, representing a range of severity from mild to severe levels of dependency.  
The score range is from 0 to 15, with higher scores indicating greater dependence.
8.2.2.2.
EuroQOL-5D
The EQ-5D is a standardized measure of health status that provides a measure of health-related 
quality of life that is widely used in clinical trials.  For this study, the EQ-5D will be a caregiver 
proxy assessment.  The assessment will be completed by the caregiver and will assess the 
caregiver’s impressions of how the subject would rate his/her own quality of life.  The EQ-5D 
questionnaire consists of 2 components: the EQ-5D descriptive system and the EQ visual 
analogue scale.  The EQ-5D descriptive system includes 5 dimensions:  mobility, self-care, usual 
activities, pain/discomfort, and anxiety/depression.  The EQ-visual analogue scale records 
overall health status on a 20-cm vertical line, with a score of 0 (worst health one can imagine) to 
100 (best health one can imagine).


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 44 of 54
12 May 2016
CONFIDENTIAL
9.
DATA MANAGEMENT
For this study, subject data will be entered into Axovant Sciences defined eCRFs, transmitted 
electronically to Axovant Sciences or designee, and combined with data provided from other 
sources in a validated data system.
Management of clinical data will be performed in accordance with applicable WCT standards 
and data cleaning procedures to ensure the integrity of the data (e.g., correcting errors and 
inconsistencies in the data).
AEs and medical history terms will be coded using an agreed version of the Medical Dictionary 
for Regulatory Activities (MedDRA), using WCT coding conventions.
Concomitant medications will be coded using the World Health Organization (WHO) 
Anatomical Therapeutic Chemical (ATC) classification 
(http://www.whocc.no/filearchive/publications/1_2013guidelines.pdf).
The eCRFs (including queries and audit trails) will be retained by Axovant Sciences, and copies 
will be sent to the investigator to maintain as the investigator copy.


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 45 of 54
12 May 2016
CONFIDENTIAL
10.
STATISTICAL CONSIDERATIONS AND DATA ANALYSES
10.1.
Hypotheses
Not Applicable.
10.2.
Sample Size Considerations
Enrollment in this study will be based on the completion rate of the lead-in study (RVT-101-
3001) and is estimated to be no more than 1150 subjects.
10.3.
Data Analysis Considerations
10.3.1.
Analysis Populations
One population will be considered in the statistical analysis of this study. 
The Safety Population will consist of subjects who have taken at least 1 dose of investigational 
product. The primary population for safety analyses will be the Safety Population.
10.3.2.
Interim Analysis
No interim analyses are planned.
10.4.
Key Elements of Analysis Plan
All safety measures over the course of the study will be presented.  Data will be listed and 
tabulated by the treatment groups assigned in the lead-in study and by overall; descriptive 
statistics will be presented for all safety parameters. Continuous data will be summarized by 
means, SDs, medians, maximum, minimum, and number of subjects.  Categorical data will be 
summarized by counts and percentages. No inferential statistical analyses of safety parameters 
will be conducted.
10.4.1.
Primary Efficacy Analyses
The efficacy analyses for DS and EQ-5D assessments will be listed and tabulated by the 
treatment groups assigned in the lead-in study and by overall. Details on the scoring, data 
imputation, and transformation will be provided in the statistical analysis plan.
10.4.2.
Safety Analyses
The safety analyses will be based on the Safety Population.
The duration of RVT-101 exposure will be derived for this study. The cumulative RVT-101
exposure, including duration on RVT-101 from the lead-in study, will also be presented.
Safety and tolerability will be assessed by summarizing and analyzing AEs, discontinuations due 
to AEs, laboratory analytes, vital signs, ECG parameters, physical examination findings, C-SSRS 
scores, and concomitant medications.


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 46 of 54
12 May 2016
CONFIDENTIAL
10.4.2.1.
Adverse Events
AEs will be considered treatment-emergent (TEAEs) if they start or worsen after first dose of the 
open-label treatment.  If an AE begins or worsens on the first day of investigational product 
administration, a CRF and source data note will be provided to clarify whether it occurred prior 
to or after investigational product administration.  TEAEs, SAEs including deaths, AEs that lead 
to discontinuation of investigational product, and AEs by maximum severity and relationship to 
investigational product will be summarized by MedDRA system organ class (SOC) and preferred 
term.  TEAEs will also be summarized by preferred term, sorted by decreasing frequency within 
SOC.  AEs will be summarized separately for the Open-Label Treatment Period and the Follow-
up Period.
10.4.2.2.
Clinical Laboratory Tests
Summaries of clinical laboratory data will be provided for subjects in the Safety Population.
Quantitative values and change from baseline in quantitative values will be summarized by 
planned visit for each quantitative laboratory value.  Listings of all laboratory results and 
reference ranges will be provided.  For multiple lab assessments at the same visit, the worst value 
will be used for the data summaries.
Laboratory values that fall outside of the reference range will be flagged as H=High or L=Low.
A lab shift table may be provided to show the baseline to the worst post baseline value.
Laboratory values that do not meet the laboratory abnormalities will be assigned N=normal in 
the shift table.
10.4.2.3.
Vital Signs, Electrocardiograms, Physical Findings, and Other Safety 
Evaluations
Descriptive summaries of medical history, vital signs, weight, and ECG parameters will be 
presented separately for each study visit.  Clinically significant abnormal ECG findings will be 
summarized by study visit.
Abnormal physical examination findings will be summarized to include the number and 
percentage of subjects experiencing each treatment-emergent abnormal physical finding.
Concomitant medications will be coded using the WHO ATC classification 
(http://www.whocc.no/filearchive/publications/1_2013guidelines.pdf).
10.4.2.4.
Suicidality
A subject data listing of all answers of the C-SSRS questionnaire will be presented.  The number 
and percentage of subjects reporting suicidal ideation and behavior will be summarized.  
Additional summaries may be provided if data warrant.  Details will be provided in the Statistical 
Analysis Plan (SAP).


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 47 of 54
12 May 2016
CONFIDENTIAL
10.4.3.
Other Analyses
Additional analyses of the data may be conducted as deemed appropriate and will be detailed in 
the SAP.  Further analyses of the data not specified in the SAP may be undertaken as post-hoc 
analyses after completion of the study.  Results of all study assessments will be included in an
appendix to the study report.


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 48 of 54
12 May 2016
CONFIDENTIAL
11.
RESPONSIBILITIES
11.1.
Investigator Responsibilities
11.1.1.
Good Clinical Practice
The investigator will ensure that this study is conducted in accordance with the principles of the 
“Declaration of Helsinki” (as amended in Edinburgh, Tokyo, Venice, Hong Kong, and South 
Africa), International Conference on Harmonisation (ICH) guidelines, or with the laws and 
regulations of the country in which the research is conducted, whichever affords the greater 
protection to the study subject.  The investigator will ensure that the basic principles of “Good 
Clinical Practice,” as outlined in 21 Code of Federal Regulations (CFR) 312, subpart D, 
“Responsibilities of Sponsors and Investigators,” 21 CFR, part 50, 1998, and 21 CFR, part 56, 
1998, are adhered to.  These standards are consistent with the requirements of the European 
Community Directive 2001/20/EC, which shall be adhered to.
Since this is a “covered” clinical trial, the investigator will ensure that 21 CFR, Part 54, 1998, is 
adhered to; a “covered” clinical trial is any “study of a drug or device in humans submitted in a 
marketing application or reclassification petition subject to this part that the applicant or FDA 
relies on to establish that the product is effective (including studies that show equivalence to an 
effective product) or that make a significant contribution to the demonstration of safety.”  This 
requires that investigators and all sub-investigators must provide documentation of their financial 
interest or arrangements with Axovant Sciences, or proprietary interests in the drug being 
studied.  This documentation must be provided before participation of the investigator and any 
sub-investigator.  The investigator and sub-investigator agree to notify Axovant Sciences of any 
change to reportable interests during the study and for 1 year following completion of the study.  
Study completion is defined as the date that the last subject has completed the protocol defined 
activities.
This study is also subject to and will be conducted in accordance with 21 CFR, part 320, 1993, 
“Retention of Bioavailability and Bioequivalence Testing Samples.”
11.1.2.
Institutional Review Board/Independent Ethics Committee Approval
This protocol and any accompanying material to be provided to the subject (such as 
advertisements, subject information sheets, or descriptions of the study used to obtain informed 
consent) will be submitted by the investigator to an IRB or IEC.  Approval from the IRB or IEC 
must be obtained before starting the study and should be documented in a letter to the 
investigator specifying the protocol number, protocol version, protocol date, documents
reviewed, and date on which the committee met and granted the approval.
Any modifications made to the protocol or other documents described in the above paragraph 
after receipt of IRB or IEC approval must also be submitted to the IRB or IEC for approval 
before implementation.


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 49 of 54
12 May 2016
CONFIDENTIAL
11.1.3.
Informed Consent
The investigator is responsible for obtaining written informed consent from each individual 
participating in this study after adequate explanation of the aims, methods, objectives, and 
potential hazards of the study and before undertaking any study-related procedures.  The 
investigator must utilize an IRB- or IEC-approved consent form for documenting written 
informed consent.  Each informed consent will be appropriately signed and dated by the subject 
or the subject’s legally authorized representative and the person obtaining consent. Consent from 
both the caregiver and subject will be obtained.
11.1.4.
Confidentiality
The investigator must assure that subjects’ anonymity will be strictly maintained and that their 
identities are protected from unauthorized parties.  Only subject initials, date of birth, and an 
identification code (ie, not names) as permitted by national regulations should be recorded on
any form or biological sample submitted to the sponsor, IRB or IEC, or laboratory.  The 
investigator must keep a screening log showing codes, names, and addresses for all subjects 
screened and for all subjects enrolled in the trial.
The investigator agrees that all information received from Axovant Sciences, including but not 
limited to the Investigator’s Brochure, this protocol, eCRFs, the investigational product, and any 
other study information, remain the sole and exclusive property of Axovant Sciences during the 
conduct of the study and thereafter.  This information is not to be disclosed to any third party 
(except employees or agents directly involved in the conduct of the study or as required by law) 
without prior written consent from Axovant Sciences.  The investigator further agrees to take all 
reasonable precautions to prevent the disclosure by any employee or agent of the study site to 
any third party or otherwise into the public domain.
11.1.5.
Study Files and Retention of Records
The investigator must maintain adequate and accurate records to enable the conduct of the study 
to be fully documented and the study data to be subsequently verified.  These documents should 
be classified into at least the following 2 categories: (1) investigator’s study file, and (2) subject 
clinical source documents.
The investigator’s study file will contain the protocol/amendments, eCRF and query forms, IRB 
or IEC and governmental approval with correspondence, informed consent, drug records, staff 
curriculum vitae and authorization forms, and other appropriate documents and correspondence.
The required source data should include sequential notes containing at least the following 
information for each subject:
Documentation that subject meets eligibility criteria, i.e., history, physical examination, 
and confirmation of diagnosis (to support inclusion and exclusion criteria);
Participation in trial (including trial number);


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 50 of 54
12 May 2016
CONFIDENTIAL
Trial discussed and date of informed consent;
Dates of all visits;
Documentation that protocol specific procedures were performed;
Results of safety parameters, as required by the protocol;
Start and end date of investigational product (including dose regimen, dispensing and 
return);
Record of all AEs (start and end date, causality and intensity);
Concomitant medication (including start and end dates, dose, and dose changes;
Date of trial completion and reason for early discontinuation, if applicable.
All clinical study documents must be retained by the investigator until at least 2 years after the 
last approval of a marketing application in an ICH region (i.e., United States, Europe, or Japan) 
and until there are no pending or contemplated marketing applications in an ICH region; or, if no 
application is filed or if the application is not approved for such indication, until 10 years after 
the investigation is discontinued and regulatory authorities have been notified.  Investigators may 
be required to retain documents longer if required by applicable regulatory requirements, by 
local regulations, or by an agreement with Axovant Sciences.  The investigator must notify 
Axovant Sciences before destroying any clinical study records.
Should the investigator wish to assign the study records to another party or move them to another 
location, Axovant Sciences must be notified in writing in advance.
If the investigator cannot guarantee this archiving requirement at the study site for any or all of 
the documents, special arrangements must be made between the investigator and Axovant 
Sciences to store these in sealed containers outside of the site so that they can be returned sealed 
to the investigator in case of a regulatory audit.  When source documents are required for the 
continued care of the subject, appropriate copies should be made for storage outside of the site.
11.1.6.
Electronic Case Report Forms
For each subject enrolled, an eCRF must be completed and signed by the principal investigator 
or sub-investigator (as appropriate) within a reasonable time period after data collection.  This 
also applies to records for those subjects who fail to complete the study (even during the
screening period if an eCRF was initiated).  If a subject withdraws from the study, the reason 
must be noted on the eCRF.  If a subject is withdrawn from the study because of a treatment-
limiting AE, thorough efforts should be made to clearly document the outcome.
11.1.7.
Drug Accountability
The investigator or designee (ie, pharmacist) is responsible for ensuring adequate accountability 
of all used and unused investigational product.  This includes acknowledgment of receipt of each 
shipment of investigational product (quantity and condition), subject dispensing records, and 


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 51 of 54
12 May 2016
CONFIDENTIAL
returned or destroyed investigational product.  Dispensing records will document quantities 
received from Axovant Sciences and quantities dispensed to subjects, including lot number, date 
dispensed, subject identifier number, subject initials (if permitted by national regulations), and 
the initials of the person dispensing the investigational product.
The investigator or his/her designee will be responsible for maintaining accurate records of 
investigational product dispensing and collection and for returning all unused investigational 
product to Axovant Sciences or its designee at the end of the study.  The instructions and address 
for returning unused investigational product will be provided in a separate document.
All investigational product supplies and associated documentation will be periodically reviewed 
and verified by the study monitor over the course of the study.
11.1.8.
Inspections
The investigator should understand that source documents for this trial should be made available 
to appropriately qualified personnel from Axovant Sciences or its representatives, to IRBs or 
IECs, or to regulatory authority or health authority inspectors.
11.1.9.
Protocol Compliance
The investigator is responsible for ensuring the study is conducted in accordance with the 
procedures and evaluations described in this protocol.
11.2.
Sponsor Responsibilities
11.2.1.
Protocol Modifications
Protocol modifications, except those intended to reduce immediate risk to study subjects, may be 
made only by Axovant Sciences.  All protocol modifications must be submitted to the IRB or 
IEC in accordance with local requirements.  Approval must be obtained before changes can be 
implemented.
11.2.2.
Study Report and Publications
A clinical study report will be prepared and provided to the appropriate regulatory agencies.  
Axovant Sciences will ensure that the report meets the standards set out in the ICH Guideline for 
Structure and Content of Clinical Study Reports (ICH E3).  Note that an abbreviated report may 
be prepared in certain cases.
After conclusion of the study and without prior written approval from Axovant Sciences, 
investigators in this study may communicate, orally present, or publish in scientific journals or 
other scholarly media only after the following conditions have been met:
the results of the study in their entirety have been publicly disclosed by or with the 
consent of Axovant Sciences in an abstract, manuscript, or presentation form; or
the study has been completed at all study sites for at least 5 years.


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 52 of 54
12 May 2016
CONFIDENTIAL
No such communication, presentation, or publication will include Axovant Sciences’ 
confidential information (see Section 11.1.4).
The investigator will submit any proposed publication or presentation along with the respective 
scientific journal or presentation form at least 30 days before submission of the publication or 
presentation.  The investigator will comply with Axovant Sciences’ request to delete references 
to its confidential information (other than the study results) in any paper or presentation and 
agrees to withhold publication or presentation for an additional 60 days in order to obtain patent 
protection if deemed necessary.
11.2.3.
Posting of Information on Publicly Available Clinical Trial Registers
Study information from this protocol will be posted on publicly available clinical trial registers 
before enrollment of subjects begins. Results will be posted as required.
11.3.
Joint Investigator/Sponsor Responsibilities
11.3.1.
Access to Information for Monitoring
In accordance with ICH Good Clinical Practice (ICH GCP) guidelines, the study monitor must 
have direct access to the investigator’s source documentation in order to verify the data recorded 
in the eCRFs for consistency and accuracy.
The monitor is responsible for routine review of the eCRFs at regular intervals throughout the 
study to verify adherence to the protocol and the completeness, consistency, and accuracy of the 
data being entered on them.  The monitor should have access to any subject records needed to 
verify the entries on the eCRFs.  The investigator agrees to cooperate with the study monitors to 
ensure that any problems detected in the course of these monitoring visits are resolved.
11.3.2.
Access to Information for Auditing or Inspections
Representatives of regulatory authorities or of Axovant Sciences may conduct inspections or 
audits of the clinical study.  If the investigator is notified of an inspection by a regulatory 
authority the investigator agrees to notify Axovant Sciences regulatory contact immediately.  
The investigator agrees to provide to representatives of a regulatory agency or Axovant Sciences 
access to records, facilities, and personnel for the effective conduct of any inspection or audit.
11.3.3.
Study Discontinuation
The sponsor reserves the right to terminate the study at any time.  Should this be necessary, both 
parties will arrange discontinuation procedures and notify the appropriate regulatory authorities, 
IRBs, and IECs.  In terminating the study, Axovant Sciences and the investigator will assure that 
adequate consideration is given to the protection of the subjects’ interests.  The investigator may 
discontinue participation in the study at any time.  However, the obligations to provide study 
results for subjects and reports to ethics committees shall continue as required by this protocol 
and applicable laws and regulations.


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 53 of 54
12 May 2016
CONFIDENTIAL
12.
REFERENCES
Alzheimer’s Association. 2013 Alzheimer’s disease facts and figures. Alzheimers Dement.
2013;9(2):208-245.
Aricept (donepezil hydrochloride) Package Insert. Woodcliff Lake, NJ: Eisai Inc.; 2013.
Benhamu B, Martin-Fontecha M, Vazquez-Villa H, et al. Serotonin 5-HT6 receptor antagonists 
for the treatment of cognitive deficiency in Alzheimer’s disease. J Med Chem.
2014;57(17):7160-7181.
Brickman AM, Riba A, Bell K, et al.. Longitudinal assessment of patient dependence in 
Alzheimer disease. Arch Neurol. 2002;59(8):1304-1308.
Cummings JL. Alzheimer’s Disease. N Engl J Med. 2004;351:56-67.
Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, et al. The Neuropsychiatric 
Inventory: comprehensive assessment of psychopathology in dementia. Neurology.
1994;44:2308-2314.
Cummings JL, Morstorf T, Zhong K. Alzheimer’s disease drug-development pipeline: few 
candidates, frequent failures. Alzheimers Res Ther. 2014;6:37.
Folstein MF, Folstein SE, McHugh PR. “Mini-Mental State”: A practical method for grading the 
cognitive state of patients for the clinician. J Psychiatry Res. 1975;12:189-198.
Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical 
trials in Alzheimer’s disease. Alzheimer Dis Assoc Disord. 1997;Suppl 2:S33-39.
James BD, Leurgans SE, Hebert LE, et al. Contribution of Alzheimer disease to mortality in the 
United States. Neurology. 2014;82:1045-50.
Kiss JZ, Tonsoco E, Djebbara Z, et al. The role of neural cell adhesion molecules in plasticity 
and repair. Brain Res Brain Res Rev. 2001;36:175-184.
McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s 
disease: recommendations from the National Institute on Aging- Alzheimer’s Association 
workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement.
2011;7(3):263-269.
Mitchell ES, Neumaier JF. 5-HT6 receptors: a novel target for cognitive enhancement. 
Pharmacol Ther. 2005;108:320-333.


Axovant Sciences Ltd.
Protocol RVT-101-3002 v2.0
Page 54 of 54
12 May 2016
CONFIDENTIAL
Mohs RC, Knopman D, Petersen RC, et al. Development of cognitive instruments for use in 
clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that 
broaden its 
scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc 
Disord. 1997;11(Suppl 2):S13–21.
Panisset M, Gauthier S, Moessler H, Windisch M, The Cerebrolysin Study Group. Cerebrolysin 
in Alzheimer’s disease: a randomized, double-blind, placebo-controlled trial with a neurotropic 
agent. J Neural Transm. 2002;109:1089-1104.
Rabin R, deCharro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med.
2001;33(5):337-343.
Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry.
1984;141:1356-1364.
Schneider L, Olin J, Doody R, et al. and the ADCS. Validity and reliability of the Alzheimer’s 
disease cooperative study-clinical global impression of change. Alzheimer Dis Assoc Disord.
1997;11(2):S22-S32.
Seki T, Arai Y. Distribution and possible roles of the polysialylated neural cell adhesion 
molecule (NCAM-H) in the developing and adult central nervous system. Neurosci Res.
1993;17:265-290.
Tiseo PJ, Rogers SL, Friedhoff LT. Pharmacokinetic and pharmacodynamics profile of donepezil 
HCl following evening administration. Br J Clin Pharm. 1998;46:Suppl 1:13-18.
Wimo A, Wetterholm AL, Mastey V, Winblad B. Evaluation of the resource utilization and 
caregiver time in Anti-dementia drug trials - a quantitative battery. In: Wimo A, Jonsson B, 
Karlsson G, Winblad B, editors. The Health Economics of dementia. London: John Wiley & 
Sons; 1998. Pp1. 465-499.